Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAT7205
- Development stage
- Phase 1
- Lead developer
- Bio-Thera Solutions
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BAT7205 is an investigational bifunctional fusion protein developed by Bio-Thera Solutions for the treatment of locally advanced or metastatic solid tumors. It consists of an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody fused to an interleukin-15 (IL-15) and IL-15 receptor alpha (IL-15Rα) sushi domain. This dual-action molecule is designed to simultaneously block the PD-1/PD-L1 immunosuppressive checkpoint and provide targeted IL-15-mediated immune stimulation. By binding to PD-L1, BAT7205 localizes IL-15 directly to the tumor microenvironment, where it activates tumor-infiltrating CD8+ T cells and natural killer (NK) cells, potentially enhancing antitumor efficacy while minimizing systemic toxicity associated with recombinant IL-15.
- Other names
- anti-PD-L1/IL-15 bi-functional fusion proteinanti-PD-L1/IL-15 bispecific antibody
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on BAT7205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAT7205.